Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2010; 135(34/35): 1694-1698
DOI: 10.1055/s-0030-1262464
DOI: 10.1055/s-0030-1262464
Kommentar | Commentary
Gastroenterologie© Georg Thieme Verlag KG Stuttgart · New York
Therapie des Morbus Crohn: Step-up oder Top-down?
Treatment of Crohn’s disease: step-up or top-down?Further Information
Publication History
eingereicht: 27.4.2010
akzeptiert: 22.7.2010
Publication Date:
18 August 2010 (online)

Schlüsselwörter
Morbus Crohn - Infliximab - Azathioprin - opportunistische Infektionen - Lymphom - Step-up - Top-down
Keywords
Crohn's disease - infliximab - azathioprine - opportunistic infections - lymphoma - step-up - top-down
Literatur
- 1
Andus T. et al .
[Suspected cases of severe side
effects after infliximab (Remicade) in Germany].
Med
Klin .
2003;
98
429-436
MissingFormLabel
- 2
Baert F. et
al .
Mucosal healing predicts sustained clinical remission
in patients with early-stage Crohn’s disease.
Gastroenterology.
2010;
138
463-468
MissingFormLabel
- 3
Beaugerie L. et al .
Lymphoproliferative disorders in patients
receiving thiopurines for inflammatory bowel disease: a prospective
observational cohort study.
Lancet.
2009;
374
1617-1625
MissingFormLabel
- 4
Biancone L, Calabrese E, Petruzziello C, Pallone F.
Treatment with biologic
therapies and the risk of cancer in patients with IBD.
Nat
Clin Pract Gastroenterol Hepatol.
2007;
4
78-91
MissingFormLabel
- 5
Bongartz T, Sutton A J, Sweeting M J, Buchan I, Matteson E L, Montori V.
Anti-TNF
antibody therapy in rheumatoid arthritis and the risk of serious
infections and malignancies.
JAMA.
2006;
295
2275-2285
MissingFormLabel
- 6
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R.
A controlled double blind study of azathioprine
in the management of Crohn’s disease.
Gut.
1995;
37
674-678
MissingFormLabel
- 7
Carmona L. et al .
Effectiveness of recommendations to prevent
reactivation of latent tuberculosis infection in patients treated
with tumor necrosis factor antagonists.
Arthritis Rheum.
2005;
52
1766-1772
MissingFormLabel
- 8
Colombel J F. et al .
The safety profile of infliximab in patients
with Crohn’s disease.
Gastroenterology.
2004;
126
19-31
MissingFormLabel
- 9
Colombel J F. et al .
Adalimumab for maintenance of clinical
response and remission in patients with Crohn’s disease.
Gastroenterology.
2007;
132
52-65
MissingFormLabel
- 10
Colombel J F. et al .
Infliximab, azathioprine, or combination
therapy for Crohn’s disease.
N Engl J Med.
2010;
362
1383-1395
MissingFormLabel
- 11
Cosnes J. et al .
Long-term evolution of disease behavior
of Crohn’s disease.
Inflamm Bowel Dis.
2002;
8
244-250
MissingFormLabel
- 12
Cosnes J. et al .
Impact of the increasing use of immunosuppressants
in Crohn’s disease on the need for intestinal surgery.
Gut.
2005;
54
237-241
MissingFormLabel
- 13
Cullen G, Keegan D, Mulcahy H E, O’Donoghue D P.
A
5-year prospective observational study of the outcomes of international
treatment guidelines for Crohn’s disease.
Clin
Gastroenterol Hepatol.
2009;
7
323-328
MissingFormLabel
- 14
D’Haens G. et al .
Early combined immunosuppression or conventional
management in patients with newly diagnosed Crohn’s disease.
Lancet.
2008;
371
660-667
MissingFormLabel
- 15
Faubion Jr W A. et al .
The natural history of corticosteroid
therapy for inflammatory bowel disease.
Gastroenterology.
2001;
121
255-260
MissingFormLabel
- 16
Frøslie K F. et al .
Mucosal
healing in inflammatory bowel disease.
Gastroenterology.
2007;
133
412-422
MissingFormLabel
- 17
Gasche C. et al .
A simple classification of Crohn’s disease.
Inflamm Bowel Dis.
2000;
6
8-15
MissingFormLabel
- 18
Hanauer S B. et al .
Maintenance infliximab for Crohn’s
disease.
Lancet.
2002;
359
1541-1549
MissingFormLabel
- 19
Ho G T. et al .
The efficacy of corticosteroid therapy
in inflammatory bowel disease.
Aliment Pharmacol Ther.
2006;
24
319-330
MissingFormLabel
- 20
Hoffmann J C. et al .
[Clinical practice guideline on diagnosis
and treatment of Crohn’s disease].
Z Gastroenterol.
2008;
46
1094-1146
MissingFormLabel
- 21
Keane J. et al .
Tuberculosis associated with infliximab,
a tumor necrosis factor alpha-neutralizing agent.
N Engl
J Med.
2001;
345
1098-1104
MissingFormLabel
- 22
Ljung T. et al .
Infliximab in inflammatory bowel disease.
Gut.
2004;
53
849-853
MissingFormLabel
- 23
Louis E. et al .
Behaviour of Crohn’s disease according
to the Vienna classification.
Gut.
2001;
49
777-782
MissingFormLabel
- 24
Markowitz J, Grancher K, Kohn N, Lesser M, Daum F.
A multicenter trial of 6-mercaptopurine and prednisone in children
with newly diagnosed Crohn’s disease.
Gastroenterology.
2000;
119
895-902
MissingFormLabel
- 25
Modigliani R. et al .
Clinical, biological, and endoscopic picture
of attacks of Crohn’s disease.
Gastroenterology.
1990;
98
811-818
MissingFormLabel
- 26
Moum B. et
al .
Clinical course during the 1st year after diagnosis
in ulcerative colitis and Crohn’s disease.
Scand
J Gastroenterol.
1997;
32
1005-1012
MissingFormLabel
- 27
Munkholm P, Langholz E, Davidsen M, Binder V.
Frequency of glucocorticoid
resistance and dependency in Crohn’s disease.
Gut.
1994;
35
360-362
MissingFormLabel
- 28
Oostenbrug L E. et al .
Clinical outcome of Crohn’s disease
according to the Vienna classification.
Eur J Gastroenterol
Hepatol.
2006;
18
255-261
MissingFormLabel
- 29
Rahier J F. et al .
European evidence-based Consensus on the
prevention, diagnosis and management of opportunistic infections
in inflammatory bowel disease.
J Crohn’s Dis
Colitis.
2009;
3
47-91
MissingFormLabel
- 30
Ramadas A V. et al .
Natural history of Crohn’s disease
in a population-based cohort from Cardiff (1986 – 2003).
Gut,.
epub 21.7.2010 ;
MissingFormLabel
- 31
Romberg-Camps M J. et al .
Influence of phenotype at
diagnosis and of other potential prognostic factors on the course
of inflammatory bowel disease.
Am J Gastroenterol.
2009;
104
371-383
MissingFormLabel
- 32
Schreiber S. et al .
Maintenance therapy with certolizumab pegol
for Crohn’s disease.
N Engl J Med.
2007;
357
239-250
MissingFormLabel
- 33
Shale M, Kanfer E, Panaccione R, Ghosh S.
Hepatosplenic T cell lymphoma
in inflammatory bowel disease.
Gut.
2008;
57
1639-1641
MissingFormLabel
- 34
Silverberg M S. et al .
Toward an integrated clinical, molecular
and serological classification of inflammatory bowel disease.
Can J Gastroenterol.
2005;
19
Suppl A
5-36
MissingFormLabel
- 35
Toruner M. et al .
Risk factors for opportunistic infections
in patients with inflammatory bowel disease.
Gastroenterology.
2008;
134
929-936
MissingFormLabel
- 36
Veloso F T, Ferreira J T, Barros L, Almeida S.
Clinical outcome of
Crohn’s disease.
Inflamm Bowel Dis.
2001;
7
306-313
MissingFormLabel
- 37
Wolfe F, Michaud K.
The effect of methotrexate and
anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid
arthritis in 19,562 patients during 89,710 person-years of observation.
Arthr Rheum.
2007;
56
1433-1439
MissingFormLabel
- 38
Wolters F L.
Phenotype at diagnosis predicts recurrence rates in Crohn’s
disease.
Gut.
2006;
55
1124-1130
MissingFormLabel
PD Dr. Klaus Herrlinger
Abteilung für Gastroenterologie, Hepatologie
und Endokrinologie
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Phone: 0711/8101-3406
Fax: 0711/8101-3793
Email: klaus.herrlinger@rbk.de